Korea Investment CORP Reduces Stock Position in DaVita Inc. (NYSE:DVA)

Korea Investment CORP lowered its position in DaVita Inc. (NYSE:DVA - Free Report) by 15.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 25,019 shares of the company's stock after selling 4,600 shares during the quarter. Korea Investment CORP's holdings in DaVita were worth $3,742,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. MML Investors Services LLC raised its position in DaVita by 1.3% during the third quarter. MML Investors Services LLC now owns 5,300 shares of the company's stock valued at $869,000 after purchasing an additional 68 shares in the last quarter. Exchange Traded Concepts LLC increased its position in shares of DaVita by 8.3% during the 4th quarter. Exchange Traded Concepts LLC now owns 891 shares of the company's stock valued at $133,000 after purchasing an additional 68 shares during the last quarter. Impact Partnership Wealth LLC lifted its position in DaVita by 3.7% in the 4th quarter. Impact Partnership Wealth LLC now owns 1,941 shares of the company's stock worth $290,000 after buying an additional 70 shares during the last quarter. Contravisory Investment Management Inc. lifted its position in DaVita by 1.2% in the 4th quarter. Contravisory Investment Management Inc. now owns 6,082 shares of the company's stock worth $910,000 after buying an additional 73 shares during the last quarter. Finally, Nilsine Partners LLC boosted its stake in DaVita by 0.8% in the fourth quarter. Nilsine Partners LLC now owns 11,160 shares of the company's stock worth $1,669,000 after buying an additional 92 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company's stock.

Analyst Ratings Changes

Several research firms have issued reports on DVA. Cowen restated a "hold" rating on shares of DaVita in a research report on Tuesday, February 18th. Barclays raised their price target on DaVita from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price objective on DaVita in a research report on Friday, February 21st. Finally, StockNews.com downgraded shares of DaVita from a "buy" rating to a "hold" rating in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $166.33.

DaVita Stock Down 2.8 %

DVA traded down $4.37 during midday trading on Friday, reaching $149.37. The company's stock had a trading volume of 1,009,511 shares, compared to its average volume of 813,204. DaVita Inc. has a 1 year low of $125.64 and a 1 year high of $179.60. The stock's 50-day moving average is $155.75 and its 200-day moving average is $157.19. The firm has a market capitalization of $11.95 billion, a price-to-earnings ratio of 13.91, a PEG ratio of 1.07 and a beta of 1.04. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating analysts' consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. As a group, research analysts expect that DaVita Inc. will post 10.76 EPS for the current year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.